Skip To Main Content
Neal Bhatia on Muck Rack

Neal Bhatia

San Diego
As seen in: Dermatology Times, Practical Dermatology, The Practical Dermatology Podcast, Wiley Online Library, JAMA (The Journal of the American Medical Association), Healio Dermatology, HCP Live, MDEdge, MDedge Dermatology, Texas Medical Center, Journal of The American Academy of Dermatology (JAAD), Heart Rhythm, International Journal of Cardiology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Neal

Contact Neal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

GLP1s in Dermatology: Emerging Evidence and Unanswered Questions

|
By Neal Bhatia, Shanthi Narla, Samip Sheth
| consultantlive.com
GLP-1 receptor agonists, known primarily for their use among individuals with obesity, overweight, and diabetes, are increasingly being explored for their potential role in dermatology.1,2,3 The HCPLive editorial team spoke with 3 clinicians working in dermatology: Neal Bhatia, MD, the former vice president of the American Academy of Dermatology (AAD), Shanthi Narla, MD, an assistant professor of dermatology at the Medical College of Wisconsin known for her research on the intersection of...
Open in Who Shared Issue with article?

Q&A: Discussing Imsidolimab for Generalized Pustular Psoriasis, With Neal Bhatia, MD

|
By Neal Bhatia
| consultantlive.com
After the acceptance by the US Food and Drug Administration (FDA) of a Biologics License Application (BLA) for imsidolimab in generalized pustular psoriasis (GPP) was announced, the HCPLive editorial team spoke in an interview with a dermatology leader regarding this move’s significance for patients with GPP.1,2 Vanda Pharmaceuticals' investigational interleukin (IL)-36 receptor inhibitor could potentially add to the limited armamentarium of agents implemented within the GPP patient population.
Open in Who Shared View Duplicates (2) Issue with article?

Discussing the Significance of Imsidolimab’s Rate of Response in GPP, With Neal Bhatia, MD

|
By Neal Bhatia
| consultantlive.com
For individuals living with generalized pustular psoriasis (GPP), the potential for 2 flare-free years could represent a fundamental shift in what GPP treatment can offer.
Open in Who Shared View Duplicates (2) Issue with article?
See all 117 licensed articles (250 Total)